In this review:
Ofatumumab + CHOP (O-CHOP) previously untreated FL
Ofatumumab + FC in CLL
PRIMA: rituximab maintenance in FL
GA101 in heavily pretreated indolent NHL
Blinatumomab in NHL
Romidepsin in T-cell lymphomas
MLH1 polymorphisms and survival in R-CHOP-treated DLBC
Please login below to download this issue (PDF)